This article is more than 5 years old. Information may no longer be current.

Iridex gets exclusive licensing rights to intellectual property of Ocunetics

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MOUNTAIN VIEW, Calif. — Iridex has received exclusive licensing rights to all intellectual property of Ocunetics, a company that produces medical devices designed to improve surgeons' efficiency and case predictability, according to a company press release.

"Iridex will accelerate the development and commercialization of the transformative product line created by Ocunetics," Steven D. Vold, MD, cofounder of Ocunetics, said in the release. "These products have been designed to improve efficiencies in a wide range of ophthalmic surgeries."

Further terms of the deal were not disclosed, but Ocunetics products are expected to be commercialized under the Iridex brand within 18 months, the release said.